causal
Platform Changes Only mRNA Sequence Between Drugs
Once the delivery, manufacturing, and drug-like properties of an mRNA platform are proven, each new drug changes only the mRNA sequence, so technical risk becomes low and only biological risk remains, unlike traditional drugs where each molecule must be developed uniquely.
causalpending
Speaker
Matthew HarrisonEvidence Quote
“the only thing you're changing between different drugs is the sequence of the mRNA inside... the technical risk should be very low, the biology risks could still be quite high.”
Created: 11/15/2026, 7:57:10 PM
Your notes
Loading notes...